Sermorelin (GHRH 1-29)

Untested against placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received.. Corpas et al. (J Clin Endocrinol Metab, 1992; PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 1379256): 10 old men took 0.5 mg and 1 mg twice daily for 14 days each in random order, with no placebo arm; growth hormone and IGF-1 rose, more at the higher dose. Vittone et al. (Metabolism, 1997; PMID 9005976): 11 men aged 64 to 76, 6 weeks, uncontrolled; nocturnal growth hormone rose, IGF-1 did not. This site defines a randomized controlled trial People are assigned to the treatment or a comparison by chance, so the groups differ only in what they received. It is the design that can show cause and effect. as people randomly assigned to treatment or placebo, and neither study had a placebo or untreated arm, so neither of them is a randomized trial against placebo. Under review since October 2026: Vitiello et al. (Neurobiol Aging, 2006), the trial named in the cognition row, is a six-month placebo-controlled trial of GHRH(1-29) in healthy older adults and may report growth hormone and IGF-1 results; the row stays D until it is read in full. A rise in growth hormone would in any case show that the drug acted, not that health changed.

The only study of sermorelin itself that measured body composition, PMID 9005976, was open-label Everyone in the trial knows which treatment they are receiving, so expectations can shape the results, especially for symptoms people report themselves. and uncontrolled and found no change in DEXA fat or muscle, weight or BMI over 6 weeks. No randomized trial of sermorelin has measured body composition (PubMed, October 2026). The trials in this class that found lean-mass gains used different molecules: the [Nle27] analog (Khorram et al., 1997; PMID 9141536) and GHRH(1-44) at 4 mg twice daily for 3 months (Veldhuis et al., J Clin Endocrinol Metab, 2004; PMID 15579798), shown as context without grade weight. D, Route 1 No human randomized trial has been run, so the record rests on animal or mechanistic evidence only. One of the two routes to the lowest letter on EBL's scale.: untested in a randomized trial.

One placebo-controlled trial of GHRH(1-29) reports cognitive outcomes: Vitiello et al. (Neurobiol Aging, 2006; PMID 16399214), 89 healthy older adults over 6 months, better scores on several of the tests measured. It was identified by an outside audit, is being read in full, and the row is under review until then. The positive cognition trial in this drug class (Baker et al., Arch Neurol, 2012; PMID 22869065) used tesamorelin, a different molecule, and Friedman et al. (JAMA Neurol, 2013; PMID 23689947) is a brain spectroscopy substudy of that same trial, not a second trial; both are shown in this entry's caveat and carry no part of any grade here.

No human randomized trial of sermorelin or GHRH(1-29) reports a mortality, frailty or longevity endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score.. Every human study of this molecule measured hormone levels, growth velocity or short-term body composition.